- Home
- ITOS vs MNPR Comparison
ITOS vs MNPR Comparison
Compare ITOS & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- MNPR
- Stock Information
- Founded
- ITOS 2011
- MNPR 2014
- Country
- ITOS United States
- MNPR United States
- Employees
- ITOS N/A
- MNPR N/A
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- ITOS Health Care
- MNPR Health Care
- Exchange
- ITOS Nasdaq
- MNPR Nasdaq
- Market Cap
- ITOS 270.7M
- MNPR 249.5M
- IPO Year
- ITOS 2020
- MNPR 2019
- Fundamental
- Price
- ITOS $6.67
- MNPR $39.42
- Analyst Decision
- ITOS Strong Buy
- MNPR Strong Buy
- Analyst Count
- ITOS 3
- MNPR 5
- Target Price
- ITOS $25.67
- MNPR $59.50
- AVG Volume (30 Days)
- ITOS 550.0K
- MNPR 17.8K
- Earning Date
- ITOS 04-28-2025
- MNPR 05-20-2025
- Dividend Yield
- ITOS N/A
- MNPR N/A
- EPS Growth
- ITOS N/A
- MNPR N/A
- EPS
- ITOS N/A
- MNPR N/A
- Revenue
- ITOS $35,000,000.00
- MNPR N/A
- Revenue This Year
- ITOS N/A
- MNPR N/A
- Revenue Next Year
- ITOS $31.74
- MNPR N/A
- P/E Ratio
- ITOS N/A
- MNPR N/A
- Revenue Growth
- ITOS 177.89
- MNPR N/A
- 52 Week Low
- ITOS $4.80
- MNPR $1.72
- 52 Week High
- ITOS $18.75
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- ITOS 49.00
- MNPR 49.46
- Support Level
- ITOS $6.18
- MNPR $37.81
- Resistance Level
- ITOS $7.80
- MNPR $44.40
- Average True Range (ATR)
- ITOS 0.50
- MNPR 3.61
- MACD
- ITOS -0.05
- MNPR -0.38
- Stochastic Oscillator
- ITOS 29.94
- MNPR 18.32
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.